BCR and B-cell chronic lymphocytic leukemia: In a pooled retrospective analysis of four Phase I/II trials in patients with R/R CLL, inferior CRR and reduced duration of response was associated with a higher number of prior therapies (especially > 3), prior B-cell receptor (BCR) pathway inhibitor therapy (especially if refractory) and bulky adenopathy[61].